Acute coronary syndrome after infliximab therapy in a patient with Crohn's disease

World Journal of Gastroenterology

Volumn 12, Issue 38, 2006, Pages 6235-6238

  Panteris, Vasilios ^a,b   Perdiou, Anna ^a   Tsirimpis, Vasilios ^a   Karamanolis, Demetrios Georgios ^a  

^a TZANEIO GENERAL HOSPITAL OF PIRAEUS   (Greece)

^b NONE   (Greece)

Author keywords

Adverse reactions; Chrohn's disease; Infliximab; Ischemic heart disease; Myocardial infarction; TNF

Indexed keywords

ACTIVATED PROTEIN C; AMIODARONE; AZATHIOPRINE; BUDESONIDE; CLOPIDOGREL; CORTICOSTEROID; ENEMA; FIBRINOGEN; INFLIXIMAB; LOW MOLECULAR WEIGHT HEPARIN; MESALAZINE; METOPROLOL; METRONIDAZOLE; NITRATE; PREDNISOLONE; PROTEIN S; TROPONIN I; TUMOR NECROSIS FACTOR ANTIBODY;

ACTIVATED PROTEIN C RESISTANCE; ACUTE CORONARY SYNDROME; ADULT; CASE REPORT; CHRONIC DIARRHEA; CLINICAL FEATURE; CROHN DISEASE; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; ENZYME BLOOD LEVEL; FIBRINOGEN BLOOD LEVEL; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART INFARCTION; HUMAN; HYPOKINESIA; MALE; PROTEIN BLOOD LEVEL; REVIEW; T WAVE INVERSION; THORAX PAIN; TREATMENT RESPONSE;

EID: 33750625083     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i38.6235     Document Type: Review

References (17)

1. Colombel JF, Loftus EV Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, Zinsmeister AR, Sandborn WJ. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004; 126: 19-31
2. Ljung T, Karlen P, Schmidt D, Hellstrom PM, Lapidus A, Janczewska I, Sjoqvist U, Lofberg R. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004; 53: 849-853
3. Koutroubakis IE. Therapy insight: Vascular complications in patients with inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol 2005; 2: 266-272
4. Sundaram KK, Cotton R, Hart P, Jones L, Gould SR. Laboratory findings associated with thrombophilia are not more common in inflammatory bowel disease. Clin Lab Haematol 2000; 22: 243-245
5. Koutroubakis IE, Sfiridaki A, Mouzas IA, Maladaki A, Kapsoritakis A, Roussomoustakaki M, Kouroumalis EA, Manousos ON. Resistance to activated protein C and low levels of free protein S in Greek patients with inflammatory bowel disease. Am J Gastroenterol 2000; 95: 190-194
6. Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, Kostis JB, Wilson AC, Folsom AR, Wit K, Benderly M, Goldbourt U, Willeit J, Kiechl S, Yarnell JW, Sweetnam PM, Elwood PC, Cushman M, Psaty BM, Tracy RP, Tybjaerg-Hansen A, Haverkate F, de Maat MP, Fowkes FG, Lee AJ, Smith FB, Salomaa V, Harald K, Rasi R, Vahtera E, Jousilahti P, Pekkanen J, D'Agostino R, Kannel WB, Wilson PW, Tofler G, Arocha-Pinango CL, Rodriguez-Larralde A, Nagy E, Mijares M, Espinosa R, Rodriquez-Roa E, Ryder E, Diez-Ewald MP, Campos G, Fernandez V, Torres E, Marchioli R, Valagussa F, Rosengren A, Wilhelmsen L, Lappas G, Eriksson H, Cremer P, Nagel D, Curb JD, Rodriguez B, Yano K, Salonen JT, Nyyssonen K, Tuomainen TP, Hedblad B, Lind P, Loewel H, Koenig W, Meade TW, Cooper JA, De Stavola B, Knottenbelt C, Miller GJ, Cooper JA, Bauer KA, Rosenberg RD, Sato S, Kitamura A, Naito Y, Palosuo T, Ducimetiere P, Amouyel P, Arveiler D, Evans AE, Ferrieres J, Juhan-Vague I, Bingham A, Schulte H, Assmann G, Cantin B, T amarche B, Despres JP, Dagenais GR, Tunstall-Pedoe H, Woodward M, Ben-Shlomo Y, Davey Smith G, Palmieri V, Yeh JL, Rudnicka A, Ridker P, Rodeghiero F, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005; 294: 1799-1809
7. Thornton M, Solomon MJ. Crohn's disease: in defense of a microvascular aetiology. Int J Colorectal Dis 2002; 17: 287-297
8. Puli SR, Benage DD. Retinal vein thrombosis after inflliximab (Remicade) treatment for Crohn's disease. Am J Gastroenterol 2003; 98: 939-940
9. Ryan BM, Romberg M, Wolters F, Stockbrugger RW. Extensive forearm deep venous thrombosis following a severe infliximab infusion reaction. Eur J Gastroenterol Hepatol 2004; 16: 941-942
10. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003; 107: 3133-3140
11. Abedin M, Scheurich D, Reimold SC, Reimold AM. Acute coronary syndrome after infliximab infusion. Cardiol Rev 2006; 14: 50-52
12. Cambien B, Bergmeier W, Saffaripour S, Mitchell HA, Wagner DD. Antithrombotic activity of TNF-alpha. J Clin Invest 2003; 112: 1589-1596
13. Nakano M, Knowlton AA, Yokoyama T, Lesslauer W, Mann DL. Tumor necrosis factor-alpha-induced expression of heat shock protein 72 in adult feline cardiac myocytes. Am J Physiol 1996; 270: H1231-H1239
14. Nakano M, Knowlton AA, Dibbs Z, Mann DL. Tumor necrosis factor-alpha confers resistance to hypoxic injury in the adult mammalian cardiac myocyte. Circulation 1998; 97: 1392-1400
15. Irace C, Mancuso G, Fiaschi E, Madia A, Sesti G, Gnasso A. Effect of anti TNFalpha therapy on arterial diameter and wall shear stress and HDL cholesterol. Atherosclerosis 2004; 177: 113-118
16. Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, Breedveld FC, Smolen JS, Eberl G, deWoody K, Feldmann M, Maini RN. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 1999; 163: 1521-1528
17. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-245